Dysfunction of cell bioenergetics is a common feature of neurodegenerative diseases, the
most common of which is Alzheimer's disease (AD). Disrupted energy utilization implicates …

Mitochondrial dysfunction has been implicated in the pathogenesis of almost all
neurological diseases, including Alzheimer's disease (AD). Historically, a primary focus in …

Neurodegenerative proteinopathies are a group of pathologically similar, progressive
disorders of the nervous system, characterised by structural alterations within and toxic …

Cyclophilin D (CyPD) is an important mitochondrial chaperone protein whose mechanism of
action remains a mystery. It is well known for regulating mitochondrial function and coupling …

Alzheimer's disease (AD) is a detrimental neurodegenerative disease that progressively
worsens with time. Clinical options are limited and only provide symptomatic relief to AD …

Mitochondrial permeability transition pore (PTP), a (patho) physiological phenomenon
discovered over 40 years ago, is still not completely understood. PTP activation results in a …

Cyclophilin D (CypD) is a key regulator of mitochondrial permeability transition pore (mPTP)
opening. This pathophysiological phenomenon is associated with the development of …

Monoamine oxidase B (MAO-B) metabolizes dopamine and plays an important role in
oxidative stress by altering the redox state of neuronal and glial cells. MAO-B inhibitors are a …

Accumulating evidence has demonstrated that mitochondrial dysfunction is a prominent
early event in the progression of Alzheimer's disease (AD). Whether protecting mitochondrial …

Alzheimer's disease (AD) is a serious neuropathologic disease characterized by
aggregation of amyloid-β (Aβ) peptide. Aβ-mediated oxidative stress and neuroinflammation …